Health Canada has authorized a new GLP-1 medication for weight loss that is a pill taken every day, rather than weekly injections.
Eli Lilly’s Foundayo is approved for adults with obesity as well as those who are overweight and have at least one related medical problem, such as high blood pressure or sleep apnea.
In addition to promoting and maintaining weight loss, the pill is also approved to help treat Type 2 diabetes.
Eli Lilly also makes the injectable drugs Mounjaro and Zepbound, which contain the active ingredient tirzepatide. Tirzepatide acts on two receptors associated with insulin production and hunger: GLP-1 and GIP.
Competitor Novo…
Read the full article at GLOBALNEWS.CA













